271 related articles for article (PubMed ID: 22655511)
21. Deflazacort treatment of Duchenne muscular dystrophy.
Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA
J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511
[TBL] [Abstract][Full Text] [Related]
22. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.
Bonifati MD; Ruzza G; Bonometto P; Berardinelli A; Gorni K; Orcesi S; Lanzi G; Angelini C
Muscle Nerve; 2000 Sep; 23(9):1344-7. PubMed ID: 10951436
[TBL] [Abstract][Full Text] [Related]
23. Co-administration of deflazacort and doxycycline: a potential pharmacotherapy for Duchenne muscular dystrophy.
Pereira JA; Marques MJ; Santo Neto H
Clin Exp Pharmacol Physiol; 2015 Jul; 42(7):788-94. PubMed ID: 25959722
[TBL] [Abstract][Full Text] [Related]
24. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
[TBL] [Abstract][Full Text] [Related]
25. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
[TBL] [Abstract][Full Text] [Related]
26. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
Wong BL; Christopher C
J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
[TBL] [Abstract][Full Text] [Related]
27. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.
Bylo M; Farewell R; Coppenrath VA; Yogaratnam D
Ann Pharmacother; 2020 Aug; 54(8):788-794. PubMed ID: 32019318
[No Abstract] [Full Text] [Related]
28. The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy.
Bonifati DM; Witchel SF; Ermani M; Hoffman EP; Angelini C; Pegoraro E
J Neurol Neurosurg Psychiatry; 2006 Oct; 77(10):1177-9. PubMed ID: 16980656
[TBL] [Abstract][Full Text] [Related]
29. Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy.
Lit L; Sharp FR; Apperson M; Liu DZ; Walker WL; Liao I; Xu H; Ander BP; Wong B
Pharmacogenomics J; 2009 Dec; 9(6):411-8. PubMed ID: 19488064
[TBL] [Abstract][Full Text] [Related]
30. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
[TBL] [Abstract][Full Text] [Related]
31. The impact of deflazacort on puberty in Duchenne muscular dystrophy.
Dooley JM; Bobbitt SA; Cummings EA
Pediatr Neurol; 2013 Oct; 49(4):292-3. PubMed ID: 23921283
[TBL] [Abstract][Full Text] [Related]
32. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
Rutter MM; Collins J; Rose SR; Woo JG; Sucharew H; Sawnani H; Hor KN; Cripe LH; Wong BL
Neuromuscul Disord; 2012 Dec; 22(12):1046-56. PubMed ID: 22967789
[TBL] [Abstract][Full Text] [Related]
33. Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy.
Buyse GM; Goemans N; van den Hauwe M; Meier T
Pediatr Pulmonol; 2013 Sep; 48(9):912-20. PubMed ID: 23129412
[TBL] [Abstract][Full Text] [Related]
34. Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy.
Parreira SL; Resende MB; Della Corte Peduto M; Marie SK; Carvalho MS; Reed UC
Arq Neuropsiquiatr; 2007 Jun; 65(2A):245-50. PubMed ID: 17607422
[TBL] [Abstract][Full Text] [Related]
35. Myocarditis in Duchenne Muscular Dystrophy After Changing Steroids.
Abutaleb ARA; McNally EM; Khan SS; Anderson AS; Carr JC; Wilcox JE
JAMA Cardiol; 2018 Oct; 3(10):1006-1010. PubMed ID: 30167630
[TBL] [Abstract][Full Text] [Related]
36. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management.
Moxley RT; Pandya S; Ciafaloni E; Fox DJ; Campbell K
J Child Neurol; 2010 Sep; 25(9):1116-29. PubMed ID: 20581335
[TBL] [Abstract][Full Text] [Related]
37. Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy.
Anderson JE; Weber M; Vargas C
Cell Transplant; 2000; 9(4):551-64. PubMed ID: 11038071
[TBL] [Abstract][Full Text] [Related]
38. Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study.
Wong BL; Cook T; Miller H
J Comp Eff Res; 2022 Aug; 11(11):779-786. PubMed ID: 35713895
[TBL] [Abstract][Full Text] [Related]
39. Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives.
BeytÃa Mde L; Vry J; Kirschner J
Acta Myol; 2012 May; 31(1):4-8. PubMed ID: 22655510
[TBL] [Abstract][Full Text] [Related]
40. Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy.
Silva EC; Machado DL; Resende MB; Silva RF; Zanoteli E; Reed UC
Arq Neuropsiquiatr; 2012 Mar; 70(3):191-5. PubMed ID: 22392111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
